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Copyright © 2008 JCBN Summary Inflammatory changes in the gastric mucosa are commonly observed in Japanese
patients with functional dyspepsia (FD). However, detailed data regarding the relationship
between the genetic regulatory factors of inflammation and FD are not available. CD14 is an
important mediator of the inflammatory response in the first line of host defense by recogni-
tion of Lipopolysaccharide (LPS). We aimed to investigate the association between CD14
promoter C-159T polymorphism and FD in a Japanese population. 108 patients with FD and
99 non-dyspeptic subjects enrolled in this study. Dyspeptic symptoms were divided according
to Rome III criteria. CD14 gene C-159T polymorphism was determined by polymerase chain
reaction-restriction fragment length polymorphism. In the non-dyspeptics, the CD14 genotype
distribution was 28CC (28.3%), 51CT (51.5%), 21TT (21.2%). Meanwhile, the CD14 genotype
distribution in FD was 31CC (28.4%), 56CT (51.4%), 22TT (20.2%). The genotype distribu-
tion was not significantly different. There was no significant difference between two groups in
the genotype distribution. We did not found any association between CD14 genotypes and
dyspeptic patients in different gender and Helicobacter pylori infection status. No significant
association was also found between CD14 polymorphism and any of different subtypes of FD
according to Rome III while there was a weak correlation between TT genotype and PDS in
male subjects (TT vs others, OR = 3.18, 95% CI = 0.98−10.26, p = 0.06). In conclusion, our
results suggest that CD14 polymorphism is unlikely to associate with susceptibility of dyspeptic
symptoms. The role of inflammation related-gene polymorphisms to the development of
dyspepsia needs to further evaluation.
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Introduction
Functional dyspepsia (FD) is a common clinical syndrome
characterized by the presence of recurrent or chronic upper
abdominal symptoms, such as epigastric pain, early satiety,
and fullness, without anatomical or biochemical abnormality
identifiable by conventional diagnostic tests, including
upper gastrointestinal endoscopy [1]. Talley et al. have
shown that up to 25% of the population experienced these
symptoms [2]. FD is a heterogeneous condition indicated
by the variety of different pathophysiologic mechanisms
that have been demonstrated in this disorder [3], so FD does
not have a well pathophysiology. Gastrointestinal motorCD14 Polymorphism in Functional Dyspepsia
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abnormalities [4], altered visceral sensation [5] and psycho-
social factors [6] have thought to be essential in the patho-
physiology of FD. Recently, Locke et al. reported familial
clustering of FD [7]. In addition, it has been reported that G-
protein bata3 subunit gene polymorphism was associated
with FD [8, 9]. These facts suggest that the genetic factor
may play a significant role in the development of FD.
On the other hand, Helicobacter pylori (H. pylori) infec-
tion is a powerful pathogenic factor and many studies have
revealed a strong association between this organism infec-
tion and gastric disorders. H. pylori infection usually leads
to persistent colonization and chronic gastric inflammation.
According to the Roma III criteria [10], H. pylori-infected
patients, who had some chronic or recurrent upper
abdominal symptoms, with neither ulceration nor erosion in
gastroduodenal mucosa by gastrointestinal endoscopy were
diagnosed as FD. That is, there is a possibility that one of
the FD subgroups may relate to the gastric mucosal inflam-
mation, although adult FD patients frequently have motility
abnormalities of the stomach and upper small bowel
including antral hypomotility and delayed gastric emptying
[11–13].
CD14 is a important mediator of the inflammatory
response in the first line of host defense by recognition of
Lipopolysaccharide (LPS). LPS, a major component of the
outer cell wall of gram-negative bacteria, is a potent and
well-characterized inducer of inflammation [14]. After
forming a complex with the LPS-binding protein, LPS
interacts with a membrane CD14 [15, 16]. This complex
induces second-messenger and signal transduction pathways
[17]. These signals in turn activate transcription factors,
mainly nuclear factor-κB and cytokines[15, 18].
Recently it was reported that soluble CD14 levels tended
to be higher in H. pylori positives than in H. pylori negatives
[19]. Furthermore, CD14 showed a trend to be increased in
FD patients with extensive gastric inflammation and high
density of H. pylori [20]. These findings support a sentinel
role for CD14 in the mucosal inflammation response to H.
pylori.
A polymorphism in the promoter region of the CD14 gene
has been described. This polymorphism involves a C-T
substitution at base-pair –159 of the 5’ flanking region of
the CD14 gene [21]. Genotypes include the CC homozygote,
the CT heterozygote, and the TT homozygote. The TT
homozygote has been associated with increased circulating
soluble CD14 levels and a higher density of the monocyte
CD14 receptor [22].
Because of the important roles that CD14 play with
respect to LPS binding and signaling, we hypothesized that
polymorphisms in the CD14 gene promoter may affect the
severity of gastric mucosal inflammation and modify the
risk of FD. In the present study, we investigated the
prevalence of this polymorphism in patients with FD diag-
nosed according to the Roma III criteria in a Japanese popu-
lation. We also wished to asses it’s effect on the different
subtypes of FD.
Materials and Methods
Study populations
We studied 207 subjects attending the Endoscopy Center
of Fujita Health University Hospital from January 2005 to
October 2006. The subjects underwent upper gastroscopy
for their health check, secondary complete check up of
stomach cancer following to barium X ray examination, or
for the complaint of abdominal discomfort. Subjects who
have significant upper gastrointestinal findings such as
peptic ulcer disease, reflex esophagitis and malignancies
were excluded from this study. Patients with malignancies in
other organs, and had received non-steroidal anti-
inflammatory drugs, antibiotics, and H. pylori eradication
treatment were also excluded. Other diseases were also
excluded by face-to-face history and physical examination
including blood test, abdominal US and ECG. According to
the Roma III criteria, 108 FD patients were identified as
having a primary compliant of either continuous or
intermittent dyspepsia for 3 months, onset at least 6 months
before, predominantly located in upper abdomen. In 108
dyspeptic patients, 44 and 30 patients were diagnosed as
epigastric pain syndrome (EPS) and postprandial syndrome
(PDS) respectively. Subjects who had no dyspeptic symptoms
within the last 12 months were considered as non-dyspepsia
subjects. Subjects who were negative by upper gastroscopy
and negative for dyspeptic symptom with in last 12 months
were considered as healthy controls. Those who had
received or proton-pump inhibitory drugs or H2RAS during
the 4 week were excluded from healthy controls. The Ethics
Committee of Fujita Health University School of Medicine
approved the protocol and written informed consent was
obtained from all of the subjects.
Detection of H. pylori infection
The H. pylori infection status was determined on the basis
of histology, culture, the rapid urease test (RUT), and anti-
bodies to H. pylori. Infection was diagnosed when at least
one of these 4 tests was positive.
Genotyping for CD14gene
Genomic DNA was extracted from non-pathological
gastric biopsies or peripheral blood using the standard
phenol/choloroform method. Then the genotyping for C-
159T of CD14 was determined using the methods described
by Hubacek et al. [ 22]. The promoter of the CD14 was
amplified by the primers 5'-ttggtgccaacagatgaggttcac-3' and
5'-ttctttcctacacagtgggaccc-3' under the following conditions:
an initial denaturation at 95°C for 5 min, followed by 38T. Tahara et al.
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cycles of 95°C for 40 s, 60°C for 30 s, and 72°C for 40 s.
The final extension step was prolonged to 7 min. The 561 bp
PCR product (10 µl) was cleaved by AvaII (New England
Biolabs. Inc, Bevely, MA) in an appropriate buffer at 37°C
overnight. The product was digested into the fragments of
204 bp, 201 bp and 156 bp length in the presence of wild
type allele. The variant allele showed a loss of one cleavage
site resulting in the presence of fragments 360 and 201 bp in
length.
Statistical analysis
Hardy-Weinberg equilibrium of the CD14gene allele in
the healthy controls and dyspeptic patients were assessed by
χ2 statistics. Differences of CD14 genotype frequencies
among two groups were determined by the two-sided
Fisher’s exact test. The odds ratio (OR) and 95% confidence
interval (CI) were also calculated. A probability value of
less than 0.05 was considered statistically significant in all
analyses.
Results
Study population
A total of 108 dyspeptic patients, 99 non-symptomatic
healthy controls participated in this study. The characteris-
tics of the subjects are summarized in Table 1. Age and
H. pylori infection positive ratios were not significantly
different among those two groups but female sex ratio was
significantly higher in the dyspeptic patients than those of
non-symptomatic healthy controls.
CD14 genotypes
C-159T polymorphism of CD14 was investigated in all
207 subjects. The frequency of CD14 polymorphism in the
non-symptomatic healthy controls and FD did not deviate
significantly from those expected under the Hardy–
Weinberg equilibrium (p = 0.80, 0.72 respectively). In the
non-symptomatic healthy controls, the CD14 genotype
distribution was 28CC (28.3%), 51CT (51.5%), 21TT
(21.2%). Meanwhile, the CD14 genotype distribution in FD
was 31CC (28.4%), 56CT (51.4%), 22TT (20.2%). The
genotype distribution was not significantly different
(Table 2).
To further evaluate the effect of CD14 gene poly-
morphism on dyspeptic symptom, we also investigated the
prevalence of CD14 gene polymorphism in different gender
and H. pylori infection status. However, we did not found
any association between CD14 genotype and FD in different
gender and H. pylori infection status (Table 3). We also
investigated the prevalence of CD14 polymorphism in
different subtypes of FD according to Rome III. Although
there was a weak correlation between TT genotype and PDS
in male subjects (TT vs others, OR = 3.18, 95%CI = 0.98–
10.26, p = 0.06), no significant association was also found
probably due to the small number of each subyupes
(Tables 2 and 3).
Discussion
The precise pathophysiology of FD is unknown. A hetero-
geneous group of pathophysiologic mechanisms have been
implicated in the etiology of FD. Delayed gastric emptying
[23], antral hypomotility [24], diminished gastric accommo-
Table 1. Characteristics of subjects
$; χ2 test *; Mann-Whitney U test
Dyspeptics Non-dyspeptics p
Subjects (n) 108 99
Sex [male/female (%/%)] 45/64 (42/58) 61/38 (62/38) 0.004$
Mean age ± SD (y) 59.59 ± 13.15 60.39 ± 13.45 0.49*
H. pylori infection positive ratio (%) 53.7 61.6 0.26$
Table 2. CD14 C-159T polymorphism and risk of FD
Statistical analysis was performed by two-sided Fisher’s exact test.
Variables n (%) genotype/n (%) OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
CC CT TT CC vs TT CC vs CT CC vs T carriers TT vs others
Over all controls (99) 28 (28.3) 51 (51.5) 21 (21.2) Reference Reference Reference Reference
Over all FD (109) 31 (28.4) 56 (51.4) 22 (20.2) 0.95 (0.43–2.08) 1 0.99 (0.52–1.87) 1 0.98 (0.54–1.79) 1 0.94 (0.48–1.84)) 1
EPS (44) 15 30 10 0.89 (0.33–2.37) 1 1.10 (0.51–2.38) 0.85 1.04 (0.19–1.59) 1 0.84 (0.36–1.93) 0.83
PDS (30) 11 14 12 1.45 (0.54–3.93) 0.61 0.60 (0.23–1.53) 0.48 1.07 (0.50–2.17) 0.83 1.81 (0.78–4.18) 0.18
Others (17) 7 16 3 0.57 (0.13–2.48) 0.51 0.24 (0.05–0.98) 0.8 1.06 (0.40–2.79) 1 0.49 (0.13–1.79) 0.4CD14 Polymorphism in Functional Dyspepsia
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dation [25], abnormal duodenal sensitivity to acid [26],
enhanced visceral sensitivity [27], and psychological factors
[28] have all been identified in subgroups of patients with
FD, with much overlap. However, the relationship between
inflammation and clinical presentation and treatment
response is not well established in FD, although histological
inflammation has been implicated in the generation of
gastrointestinal pain or discomfort [29].
During investigation of dyspepsia, three major structural
causes are readily identifiable: peptic ulcer disease (10%),
gastroesophageal refIux (20%) (with or without esophagitis)
and malignancy (2%) [30]. It is well known that H. pylori
plays a major role in the pathogenesis of gastro-duodenal
inflammation, including gastric and duodenal ulcers.
Although H. pylori infection has been reported to be more
frequent in patients with non-ulcer dyspepsia than control
population, the role of H. pylori infection in functional dys-
pepsia is still controversial [31]. Many trials evaluating the
efficacy of H. pylori eradication treatment for FD have given
conflicting results but there is a clear indication that H.
pylori eradication treatment is effective in at least a subset of
patients with FD. The recently published meta-analysis
suggests that H. pylori eradication at 12 months has a small
but statistically significant benefit in the treatment of FD
[32]. These facts suggest that H. pylori-induced gastric
mucosal inflammation may play an important role on the
Table 3. Association between CD14 C-159T polymorphism and clinicopathological feature of FD
Statistical analysis was performed by two-sided Fisher’s exact test.
Variables n (%) genotype/n OR (95% CI) p OR (95% CI) p OR (95% CI) p OR (95% CI) p
CC CT TT CC vs TT CC vs CT CC vs T carriers TT vs others
Hp (−)
Controls (37) 9 19 10 Reference Reference Reference Reference
FD (50) 17 24 9 0.48 (0.14–1.60) 0.36 0.67 (0.24–1.83) 0.46 0.60 (0.23–1.56) 0.35 0.61 (0.20–1.71) 0.44
EPS (29) 10 15 4 0.36 (0.08–1.56) 0.29 0.71 (0.23–2.19) 0.58 0.59 (0.20–1.72) 0.42 0.45 (0.12–1.61) 0.24
PDS (19) 8 6 5 0.56 (0.13–2.36) 0.49 0.36 (0.09–1.33) 0.18 0.43 (0.13–1.39) 0.22 1.00 (0.29–3.49) 1
Others (8) 1 6 1 0.90 (0.05–16.59) 1 2.84 (0.29–27.25) 0.64 2.17 (0.23–20.10) 0.66 0.40 (0.04–3.67) 0.66
HP (+)
Controls (61) 19 31 11 Reference Reference Reference Reference
FD (59) 14 32 13 1.60 (0.55–4.62) 0.43 1.40 (0.60–3.27) 0.52 1.45 (0.65–3.26) 0.42 1.28 (0.52–3.15) 0.65
EPS (21) 5 15 5 1.73 (0.41–7.33) 0.48 1.84 (0.58–5.88) 0.41 1.81 (0.59–5.54) 0.27 1.14 (0.35–3.69) 1
PDS (14) 3 8 6 3.45 (0.72–16.64) 0.14 1.63 (0.39–6.93) 0.73 2.11 (0.54–8.22) 0.37 2.48 (0.75–8.15) 0.18
Others (13) 6 10 2 0.58 (0.10–3.36) 0.69 1.02 (0.32–3.27) 1 0.90 (0.30–2.77) 1 0.57 (0.11–2.84) 0.72
Male
Controls (61) 18 31 12 Reference Reference Reference Reference
FD (45) 11 24 11 1.50 (0.49–4.55) 0.58 1.27 (0.50–3.18) 0.65 1.33 (0.56–3.19) 0.66 1.28 (0.51–3.24) 0.64
EPS (21) 7 11 3 0.64 (0.14–2.99) 0.71 0.91 (0.30–2.77) 1 0.84 (0.29–2.42) 0.79 0.68 (0.17–2.69) 0.75
PDS (16) 3 6 7 3.50 (0.75–16.28) 0.15 1.16 (0.26–5.23) 1 1.81 (0.46–7.14) 0.53 3.18 (0.98–10.26) 0.06
Others (9) 1 7 1 1.50 (0.09–26.36) 1 4.06 (0.46–35.75) 0.25 3.35 (0.39–28.76) 0.43 0.51 (0.06–4.48) 1
Female
Controls (38) 10 19 9 Reference Reference Reference Reference
FD (64) 20 33 11 0.61 (0.19–1.96) 0.55 0.87 (0.34–2.24) 0.81 0.79 (0.32–1.92) 0.66 0.67 (0.25–1.80) 0.45
EPS (32) 8 18 6 0.83 (0.21–3.34) 1 1.18 (0.38–3.67) 1 1.07 (0.36–3.15) 1 0.74 (0.23–2.37) 0.77
PDS (20) 8 8 4 0.56 (0.12–2.49) 0.48 0.53 (0.15–1.83) 0.35 0.54 (0.17–1.69) 0.37 0.81 (0.21–3.04) 1
Others (18) 6 10 2 0.37 (0.06–2.32) 0.4 0.88 (0.25–3.12) 1 0.710.21–2.41) 0.79 0.40 (0.08–2.10) 0.47
Different generation
<60
Controls (37) 7 19 11 Reference Reference Reference Reference
FD (48) 14 25 9 0.41 (0.12–1.45) 0.21 0.66 (0.26–1.64) 0.59 0.590.20–1.59) 0.32 0.55 (0.20–1.50) 0.3
EPS (25) 8 14 3 0.24 (0.05–1.22) 0.13 0.64 (0.19–2.20) 0.54 0.5 (0.15–1.61) 0.36 0.32 (0.08–1.30) 0.13
PDS (15) 5 5 5 0.64 (0.13–3.03) 0.7 0.37 (0.08–1.67) 0.25 0.47 (0.12–1.80) 0.29 1.18 (0.33–4.27) 0.77
Others (11) 2 8 1 0.32 (0.02–4.20) 0.55 1.47 (0.25–8.70) 1 1.05 (0.18–5.38) 1 0.24 (0.03–2.08) 0.25
60>=
Controls (62) 21 31 10 Reference Reference Reference Reference
FD (62) 18 31 13 1.52 (0.54–4.28) 0.6 1.17 (0.52–2.60) 0.84 1.25 (0.59–2.68) 0.7 1.38 (0.55–3.43) 0.64
EPS (29) 7 16 6 1.80 (0.48–6.77) 0.5 1.55 (0.54–4.41) 0.45 1.61 (0.59–4.38) 0.79 1.36 (0.44–4.18) 0.57
PDS (21) 6 9 6 2.10 (0.54–8.18) 0.31 1.02 (0.31–3.28) 1 1.28 (0.43–3.78) 0.79 2.08 (0.65–6.66) 0.22
Others (16) 6 8 2 0.70 (0.12–4.10) 1 0.90 (0.27–2.98) 1 0.85 (0.27–2.67) 0.78 0.74 (0.15–3.79) 1T. Tahara et al.
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pathophysiology of FD.
Recent evidence supports the relevance of a genetic
milieu in FD. A case-control study by Holtmann et al.
suggested that there is a significant link between
GNβ3 (C825T) CC genotype and functional dyspepsia [8].
The association has been independently confirmed [9].
However, there are no reports demonstrated the relationship
between the polymorphisms of molecules associated with
inflammation and FD. Depending on the population under
study, between 30%–65% of patients diagnosed with func-
tional dyspepsia has H. pylori-induced gastritis [33,  34].
Our data in the present study also showed that the positivity
of  H. pylori infection in dyspeptic patients was 53.7%.
Therefore, it is feasible that polymorphisms of the inflam-
mation-related molecule genes may interact with H. pylori-
induced gastric inflammation to the pathophysiology of one
of the FD subgroup.
In the present study, we investigated the association of the
C-159T of CD14 gene polymorphisms with FD and its
subgroups because CD14 have a sentinel role for mucosal
inflammation responce to H. pylori. It has been reported that
the transcriptional activity of the CD14-159T allele was
found, by the luciferase reporter assay, to be increased in
monocytic Mono Mac 6 cells [35]. Homozigous carriers of
the T allele also have a significant increase in serum level of
soluble CD14 and correlation with high IFNγ, which is
produced by T helper 1 (Th1) like cell [21].
It is well known that a polarized Th1 immune response
occurs in H. pylori infection [36] and Th1 dominant immune
response has been reported to cause gastric atropy and
metaplasia. It is also shown that long standing gastric
mucosal inflammation by H. pylori infection often leads to
low acid secretion in Japanese [37]. Recently, it has been
reported that intraduodenaly administrated acid affects
gastroduodenal motility as well as sensation and the role of
gastric acid in functional dyspepsia has been suggested
[38, 39]. Therefore, it is reasonable to speculate that, not
only by gastric inflammation, but also by altering gastric
acid secretion, the CD14 polymorphism may affect the
susceptibility of FD.
There was, however, no association of CD14 C-159T and
development of FD. The frequencies of CD14 genotypes
were not significantly different between FD and controls in
207 subjects. We further investigated the prevalence of
CD14 gene polymorphism in different gender and H. pylori
infection status, no significant association of CD14 C-159T
polymorphism and FD were also found in these subgroups
excluding the weak correlation between TT genotype and
PDS in male subjects.
Recently, other polymorphism have been described in the
CD14 gene that remained to be studied in FD [40]. In
addition, the frequency of the C-159T allele may show
variations in different ethnic groups. Furthermore, it has
been also reported that the GNbeta3-C825T polymorphism
which is associated with FD [8, 9] is not associated signifi-
cantly with lower FD [41], suggesting that the relationship
between FD and gene polymorphism has not been com-
pletely cleared yet.
Further genetic studies including other polymorphisms in
CD14 gene will be needed in a larger and ethnically diverse
population to resolve the impact of the CD14 poly-
morphisms in the susceptibility of FD.
In conclusion, we have shown that C-159T poly-
morphisms of CD14 is not associated with FD in Japanese.
The present study is the first investigating a potential
relationship between the C-159T polymorphism of CD14
gene and FD. Despite several potential limitations, we
believe that our study provides a salient finding even if it
was a negative one.
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